Tonix shares up 13.84% intraday as positive Phase 1 data for TNX-4800 and plans for 2027 Phase 2 study drive optimism.

Tonix Pharmaceuticals Holding Corp. surged 13.84% intraday following the announcement of positive Phase 1 data for its long-acting monoclonal antibody TNX-4800, a potential single-dose Lyme disease prophylactic. The study demonstrated safety, tolerability, and pharmacokinetics supporting approximately four months of protection, with no significant adverse events. Tonix also outlined plans for a randomized, double-blind, placebo-controlled Phase 2 field study expected to begin in H1 2027, pending FDA clearance. The data were presented at the World Vaccine Congress Washington 2026 by lead investigator Dr. Mark Klempner. The news highlights Tonix’s advancement in developing a novel, differentiated treatment for a disease with no current FDA-approved vaccines or prophylactics, generating optimism among investors.